
In a groundbreaking study, researchers utilized whole genome sequencing data to identify pharmacogenomic risk factors linked to antiseizure medication-induced cutaneous adverse drug reactions (cADRs). Analyzing Genomics England's 100,000 Genomes Project data, they found 4 HLA-B15:02 and 86 HLA-A31:01 carriers among 1043 epilepsy patients. One HLA-B15:02 carrier experienced cADRs. Notably, 16.9% of European HLA-A31:01 carriers and 14.4% of carriers, regardless of ancestry, suffered cADRs. The study highlights the vast potential of genetic data in healthcare beyond identifying disease-causing variants. Understanding pharmacogenomic biomarkers can personalize pharmacotherapy, offering tailored treatment for genetically susceptible individuals. This research opens avenues for individually customized diagnostic and therapeutic care in healthcare.
Like
Save
Share